New targets for non-small-cell lung cancer therapy

Expert Review of Anticancer Therapy

Volumn 7, Issue 10, 2007, Pages 1423-1437

  Alvarez, Manrique ^a   Roman, Eloy ^b   Santos, Edgardo S ^c   Raez, Luis E ^a,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Bevacizumab; Bortezomib; Cetuximab; Erlotinib; Matuzumab; Non small cell lung cancer; Sorafenib; Sunitinib; Targeted therapy; Trastuzumab

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATUZUMAB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; PERTUZUMAB; PLACEBO; PLATINUM; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; MONOCLONAL ANTIBODY; NEW DRUG; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; TUMOR PROTEIN;

ABDOMINAL PAIN; ADD ON THERAPY; ADVANCED CANCER; ALLERGIC REACTION; ANAPHYLAXIS; ANGIOGENESIS; ANOREXIA; APOPTOSIS; ASTHENIA; BRAIN HEMORRHAGE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CARCINOGENESIS; CAUSE OF DEATH; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; DYSPNEA; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PROGNOSIS; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; UNITED STATES; CELL DIVISION; CELL TRANSFORMATION; CLASSIFICATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; FEMALE; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; STATISTICS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS;

EID: 35848931444     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.10.1423     Document Type: Review

References (101)

1. Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J. Clin. Oncol. 19, 3210-3218 (2001).
2. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
4. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus carboplantinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21, 3016-3024 (2003).
5. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003).
6. Hoang T, Schiller JH. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev. Anticancer Ther. 2(4), 393-401 (2002).
7. Schiessinger J. Cell signaling by receptor tyrosine kinases. Cell 103(2), 211-225 (2000).
8. Bell DW, Lynch TJ, Haseriat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23(31), 8081-8092 (2005).
9. Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 18(4), 752-760 (2007).
10. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitirib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
11. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
12. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung-cancer. JAMA 290, 2149-2158 (2003).
13. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa. Survival Evaluation in Lung Cancer. Lancet 366, 1527-1537 (2005).
14. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23(31), 8081-8092 (2005).
15. Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J. Thoracic Oncol. 1(9), 965-971 (2006).
16. Giaccone G, Herbst RS, Manegold C et al. Gefinitib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
17. Herbst RS, Gioccone G, Schiller JH et al. Gefinitib in combination with paclitaxel and arboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
18. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
19. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a Phase II study. Clin. Cancer Res. 12(20 Pt 1), 6049-6055 (2006).
20. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. 25(7), 760-766 (2007).
21. Shepherd FA, Rodrigues Pereira J. Ciuleanu T et al. Ertotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
22. Gatzemeler U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncal. 25(12), 1545-1552 (2007).
23. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
24. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23(11), 2556-2568 (2005).
25. Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12(13), 3908-3914 (2006).
26. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
27. Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) with mutations in the tyrosine (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. 24(18S), S369 (2006) (Abstract 7020).
28. Morikawa. N, Inoue A, Suzuki T et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan. J. Clin. Oncol. 24(Suppl. 18), 383s (2006) (Abstract 7077).
29. Sequist LV, Martinis RG, Spigei D et al. iTARGET: a Phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. J. Clin. Oncol. 25(Suppl. 19), S386 (2007) (Abstract 7504).
30. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29(1 Suppl. 4), 27-36 (2002).
31. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin. Oncol. 21(14), 2787-2799 (2003).
32. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. 24(33), 5253-5258 (2006).
33. Thienelt CD, Bunn PA Jr, Hanna N et al. A multi-centered Phase I/ II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J. Clin. Oncol. 23(34), 8786-8793 (2005).
34. Kim ES, Mauer AM, Tran HT et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Presented at: Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology. Chicago. IL, USA (2003) (Abstract 2581).
35. Robert F, Blumenschein G, Herbst RS et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/arboplatin in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 23(36), 9089-9096 (2005).
36. Kim ES. Cetuximab as a single agent or in combination with chemotherapy in lung cancer. Clin. Lung. Cancer. 6(Suppl. 2), S80-S84 (2004).
37. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. 10(12 Pt 2), S4241-S4244 (2004).
38. Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin. Ther. Targets 11 (2), 245-257(2007).
39. Rosen R, Daniel C, Ramlau R et al. Randomized Phase II study of cetuximab in combination with cisplatin © and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Presented at: Proceedings of the 40th Annual Meeting of the Amencan Society of Clinical Oncology. New Orleans, LA, USA (2004) (Abstract 7012).
40. Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 40th Annual Meeting of the American Society of Clinical Ocology. New Orleans, LA, USA (2004) (Abstract 7083).
41. Kollmannsberger C, Schittenhelm M, Honecker F et al. A Phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 17(6), 1007-1013 (2006).
42. Ohta Y, Endo Y, Tanaka M et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res. 2, 1411-1416 (1996).
43. Lee TH, Seng S, Sekine M et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 4(6), E186 (2007).
44. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 74(1), 64-68 (1997).
45. Yano T, Tanikawa S, Fugie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur. J. Cancer. 36(5), 601-609 (2000).
46. Masuya D, Huang C, Liu D et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92(10), 2628-2638 (2001).
47. Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38(1), 51-57 (2002).
48. Presta L, Chen H, O'Cannor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
49. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
50. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
51. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin. Oncol 19(3), 851-856 (2001).
52. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
53. Novotny WF, Holmgren E, Griffing S et al. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PII) in patients with advanced NSCLC receiving bevacizumab (BV). Presented at: Procredings of the 37th Annual Meeting of the American Society of Clinical Geology. San Francisco, CA, USA (2001) (Abstract 1318).
54. Manegold C, von Pawel J, Zatloukal P et al. Randomized, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I. 25(18S) (2007) (Abstract LBA7514).
55. Wilhelm SM, Carter C, Tang LY et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2005).
56. Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother. Pharmacol. 59(2), 183-195 (2007).
57. Liu B, Barrett T, Choyke P et al. A Phase II study of BAY 43-9006 (sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J. Clin. Oncol. 24(Suppl. 18), 17119 (2006).
58. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (2006) (Abstract 7002).
59. Steinbild S, Baas F, Gmehling D et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. Presented at: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA (2005) (Abstract 3115).
60. Eisen T, Ahmad T, Gore ME et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Presented at: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA (2005) (Abstract 7508).
61. Adjei AA, Molina JR, Mandrekar S et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin. Cancer Res. 13(9), 2684-2691 (2007).
62. Richly H, Henning BF, Kupsch P et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann. Oncol. 17, 866-873 (2006).
63. Siu LL. Awada A, Takimoto CH et al. Phase I trial of sorafenib and gem-citabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer, Clin. Cancer Res. 12, 144-151 (2006).
64. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
65. Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter Phase II trial. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA (2006) (Abstract 7001).
66. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizurnab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clib. Oncol. 23(11), 2544-2555 (2005).
67. Fehrenbacher L, O'Neill V, Belani CP et al. A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (2006) (Abstract 7062).
68. Wu W, Onn A, Isobe T et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol. Cancer Ther. 6(2), 471-483 (2007).
69. Tamura T, Minami H, Yamada Y et al. A Phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thorac. Oncol. 1(9), 1002-1009 (2006).
70. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (2006) (Abstract 7000).
71. Heymach JV, Johnson BE, Prager D et al. A Phase II trial of ZD6474 plus dicetaxel in patients with previously treated NSCLC. follow-up results. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (2006) (Abstract 7016).
72. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur. J. Cancer 43(7), 1125-1133 (2007).
73. Scagliotti G. Proteasome inhibitors in lung cancer. Crit. Rev. Oncol. Hematol. 58(3), 177-189 (2006).
74. Lara PN Jr, Koczywas M, Quinn DI et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a Phase I California Cancer Consortium trial. J. Thorac. Oncol. 1(2), 126-134 (2006).
75. Fanucchi MP, Fosselia FV, Belt R et al. Randomized Phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Ciin. Oncol. 24(31), 5025-5033 (2006).
76. Davies AM, McCoy J, Lara PN et al. Bortezomib + gemcitabine (Gem)/ carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NgCLC): results of a Phase II Southwest Oncology Group (SWOG) trial (S0339). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (Suppl. 18) (2006) (Abstract 7017).
77. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18(16), 1926-1945 (2004).
78. Beevers CS, Li F. Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer. 119(4), T57-764 (2006).
79. Granville CA, Warfel N, Tsurutani J et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced marine lung tumors. Clin. Cancer Res. 13(7), 2281-2289 (2007).
80. Buck E , Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5(11), 2676-2684 (2006).
81. Kim KW, Mutter RW, Cao C et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. Biol Chem. 281(48), 36883-36890 (2006).
82. Stracke S, Ramudo L, Keller F, Henne-Bruns D, Mayer JM. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Tnasplant Proc. 38(3), 766-770 (2006).
83. Hidalgo M, Buckner JC, Erlichman C et al. A Phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12(19), 5755-5763 (2006).
84. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26(4 Suppl. 12), 60-70 (1999).
85. Kern JA, Schwarts DA, Nordberg JE et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50, 5184-5191 (1990).
86. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. 22(7), 1180-1187 (2004).
87. Zinner RG, Glisson BS, Fosselia FV et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a Phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44(1), 99-110 (2004).
88. Gatzemeier U, Groth G. Butts C et al. Randomized Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-smali-cell lung cancer. Ann. Oncol. 15, 19-27 (2004).
89. Allison DE, Malik M, Qureshi F et al. Pharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: Phase Ia results. Proc. Am. Soc. Clin. Oncol. 22, (2003) (Abstract 790).
90. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin. Cancer Rer. 11, 5300-5309 (2005).
91. Adjei AA, Mauer A, Bruzek L et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21 (9), 1760-1766 (2003).
92. Kim ES, Kies MS, Fossella FV et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 104(3), 561-569, (2005).
93. Tomozawa S, Tsuno NH, Sunami E et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer. 83(3), 324-328 (2000).
94. Aitorki NK, Keresztes RS, Port JL et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21(14), 2645-2650 (2003).
95. Csiki I, Morrow J, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a Phase II trial of celecoxib and docetaxel. Clin. Cancer Res. 11, 6634-6640 (2005).
96. Edelman MJ, Watson DM, Wang X et al. Eicosanoid modulation in advanced non-2 small cell lung cancer (NSCLC): CALGB 30203. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 24 (Suppl. 18), (2006) (Abstract 7025).
97. Tontonoz P, Singer S, Forman BM et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl Acad. Sci. USA 94(1), 237-241 (1997).
98. Khuri FR, Rigas JR, Figlin RA et al. Multi-institutional Phase I/ II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol 19(10), 2626-2637 (2001).
99. Blumenschein GR, Khuri F, Gatzemeier U et al. A randomized Phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, LA, USA (2005) (Abstract 7001).
100. Jassem J, Zatloukal P, Ramlau R et al. A randomized Phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/ vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA (ZO05) (Abstract 7024).
101. Kelly K, Chansky K, Gaspar LE et al. Updated analysis of SWOG 0023: a randomized Phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2007) (Abstract 7513).